Kota, K.K., Salazar, L.F., Culbreth, R.E. et al. Psychosocial mediators of perceived stigma and suicidal ideation among transgender women. BMC Public Health 20, 125 (2020). Abstract Background Transgender women (TGW) in the U.S. experience high rates of stigma, depression, and elevated rates of suicide. This study examined correlates of suicidal ideation and estimated the conditional indirect...
Life satisfaction and mental health among transgender students
Life satisfaction and mental health among transgender students in Norway Anderssen, N., Sivertsen, B., Lønning, K.J. et al. BMC Public Health 20, 138 (2020) Background Social attitudes to transgender persons and other gender minorities vary around the world, and in many cultures, prejudices and social stigma are common. Consequently, transgender persons face challenges related to discrimination...
STIs among transgender men and women attending Australian sexual health clinics
Med J Aust. 2019 Aug 29. doi: 10.5694/mja2.50322. [Epub ahead of print] Abstract Objectives To estimate rates of HIV infection, chlamydia, gonorrhoea, and infectious syphilis in transgender men and women in Australia; to compare these rates with those for cisgender people. Design Cross‐sectional, comparative analysis of de‐identified health data. Setting, participants We analysed data for 1260...
HIV and Trans Women: A Literature Review
Transgend Health. 2018; 3(1): 239–250 Abstract: Trans women are a key, yet under-researched, population in the HIV epidemic. However, there remains a paucity of data on the health and wellbeing of trans women at risk of, or living with, HIV in the United Kingdom. This article provides a narrative review of key empirical research into HIV among trans women. In an effort to explore individual and...
Transgender women taking PrEP have lower levels of PrEP drugs than cisgender men
aidsmap/nam, November 9th 2018 A study presented at October’s HIV Research for Prevention conference (HIVR4P) in Madrid shows that transgender women who are taking feminising hormones and also taking pre-exposure prophylaxis (PrEP) have levels of the PrEP drugs tenofovir and emtricitabine in their blood that are about 25% lower than those in cisgender men, and levels in rectal tissue cells...
The updated 2017 ASHM HIV pre-exposure prophylaxis (PrEP) Guidelines
Journal of Virus Eradication, 2017; 3: 168–184 Daily use of co-formulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines. These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine‘s...